| Mrs Maggie Elline Keck, FNP | |
|
415 Catlett Rd, Sevierville, TN 37862-5901 | |
| (865) 330-7425 | |
| (865) 333-5848 |
| Full Name | Mrs Maggie Elline Keck |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 13 Years |
| Location | 415 Catlett Rd, Sevierville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003182239 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 16632 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Blount Memorial Hospital | Maryville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blount Memorial Physician Group Inc | 6406844174 | 242 |
News Archive
Drowning is a global threat to human health. Each year, more than 372,000 people die as a result of drowning, with many of those deaths being preventable by simple water safety measures. In order to arm professionals with the most up-to-date clinical protocols, the Wilderness Medical Society has issued a new set of practice guidelines for both the treatment and prevention of drowning, published in the society's official journal, Wilderness and Environmental Medicine.
Researchers may get some indication of how aggressively an angry person will react by measuring the size relationship between a person's ears and other body parts, according to a new study.
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
› Verified 7 days ago
| Entity Name | Blount Memorial Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699710194 PECOS PAC ID: 6406844174 Enrollment ID: O20040503000547 |
News Archive
Drowning is a global threat to human health. Each year, more than 372,000 people die as a result of drowning, with many of those deaths being preventable by simple water safety measures. In order to arm professionals with the most up-to-date clinical protocols, the Wilderness Medical Society has issued a new set of practice guidelines for both the treatment and prevention of drowning, published in the society's official journal, Wilderness and Environmental Medicine.
Researchers may get some indication of how aggressively an angry person will react by measuring the size relationship between a person's ears and other body parts, according to a new study.
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
› Verified 7 days ago
| Entity Name | House Call Primary Care, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578956710 PECOS PAC ID: 8426361932 Enrollment ID: O20150713001953 |
News Archive
Drowning is a global threat to human health. Each year, more than 372,000 people die as a result of drowning, with many of those deaths being preventable by simple water safety measures. In order to arm professionals with the most up-to-date clinical protocols, the Wilderness Medical Society has issued a new set of practice guidelines for both the treatment and prevention of drowning, published in the society's official journal, Wilderness and Environmental Medicine.
Researchers may get some indication of how aggressively an angry person will react by measuring the size relationship between a person's ears and other body parts, according to a new study.
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Maggie Elline Keck, FNP 9325 S Northshore Dr, Knoxville, TN 37922-6548 Ph: (865) 330-7425 | Mrs Maggie Elline Keck, FNP 415 Catlett Rd, Sevierville, TN 37862-5901 Ph: (865) 330-7425 |
News Archive
Drowning is a global threat to human health. Each year, more than 372,000 people die as a result of drowning, with many of those deaths being preventable by simple water safety measures. In order to arm professionals with the most up-to-date clinical protocols, the Wilderness Medical Society has issued a new set of practice guidelines for both the treatment and prevention of drowning, published in the society's official journal, Wilderness and Environmental Medicine.
Researchers may get some indication of how aggressively an angry person will react by measuring the size relationship between a person's ears and other body parts, according to a new study.
Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
› Verified 7 days ago
Phyliss A. Shults, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 641 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-428-0583 Fax: 865-428-1625 | |
Meredith Cromer, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1115 Blanton Dr, Sevierville, TN 37862 Phone: 865-453-4434 Fax: 866-610-2903 | |
Jessica Williams Cooper, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 215 Forks Of The River Pkwy, Sevierville, TN 37862 Phone: 865-366-4070 Fax: 865-366-3720 | |
Jordan E Mccroskey, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 675 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-453-2039 Fax: 833-908-2175 | |
Rhonda Levada Daniels-reinalda, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1787 Veterans Blvd Ste 101, Sevierville, TN 37862 Phone: 865-428-2773 | |
Mrs. Jessica Breedlove, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 470 Collier Dr, Sevierville, TN 37862 Phone: 865-286-5421 |